Chinook Therapeutics, Inc.

The latest third quarter data from the National Venture Capital Association (NVCA) and Pitchbook’s Venture Monitor report confirm recent data compiled by Evaluate Pharma, which showed that VC investme

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the las

Data presented at the European Renal Association meeting today suggest that Novartis AG is heading to market with two therapies for different rare kidney diseases. Fabhalta (iptacopan) and atrasenta

Biogen, Inc. has been on the hunt during the past few years for outside assets that can help diversify its largely neurology-focused portfolio, and CEO Chris Viehbacher has been adamant that the comp